Maze Ⅳ in the treatment of heart valve disease with persistent atrial fibrillation in elderly patients: A cohort study
- VernacularTitle:迷宫Ⅳ术治疗心脏瓣膜病合并持续性心房颤动老年患者的队列研究
- Author:
Zhikun FU
1
,
2
;
Huijuan YANG
1
,
2
;
Xiangli ZHANG
1
,
2
;
Shuguang ZHANG
1
,
2
;
Heng YANG
1
,
2
;
Yongfeng ZHU
1
,
2
;
Peng DU
1
,
2
Author Information
1. Department of Cardiac Surgery, The Seventh People'
2. s Hospital of Zhengzhou, Cardiovascular Disease Hospital of Zhengzhou, Zhengzhou, 450012, P.R.China
- Publication Type:Journal Article
- Keywords:
Maze Ⅳ surgery;
valvular heart disease;
persistent atrial fibrillation;
elderly patients
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2020;27(12):1413-1417
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of Maze Ⅳ in the treatment of elderly patients with valvular heart disease and persistent atrial fibrillation (AF). Methods We retrospectively analyzed the clinical data of 78 elderly patients with cardiac valve disease combined with persistent AF in our hospital from 2017 to 2018. The patients were allocated to two groups including a trial group (n=37) and a control group (n=41). There were 21 males and 16 females aged 61 to 74 (65.2±2.5) years in the trial group. There were 23 males and 18 females aged 62 to 76 (64.8±3.3) years in the control group. The clinical effects of the two groups were compared. Results There was no statistical difference in baseline data between the two groups (P>0.05). The aortic occlusion time, extracorporeal circulation time, and operation time of the trial group were longer than those of the control group with statistical differences (P<0.05). There was no statistical difference in postoperative ventilator assistance time, complication rate, mortality, ICU retention time, perioperative drainage, red blood cell transfusion volume, or length of hospital stay between the two groups (P>0.05). At the time of discharge, postoperaive 1-month, 3-month, 6-month, and 12-month, the maintenance rates of sinus rhythm in the control group were statistically different from those of the trial group (P<0.05). Compared with the control group, left atrial diameter, left ventricular end diastolic diameter and the decrease of pulmonary artery systolic blood pressure were statistically different (P<0.05). Conclusion Maze Ⅳ is safe and effective in the treatment of elderly patients with valvular heart disease and persistent AF, which is conducive to the recovery and maintenance of sinus rhythm, and is beneficial to the remodeling of the left atrium and left ventricle and the reduction of pulmonary systolic blood pressure with improvement of life quality of the patients.
